SynthesisFrontiers in immunology2024

Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.

Jianguo Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.